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Beyond the Low-Hanging Fruit: Stem Cell Research Policy
in an Obama Administration
James W. Fossett*
It has been widely expected that the installation of the Obama administration
and an expanded Democratic majority in both houses of Congress would produce
a major shift in federal human embryonic stem cell (hESC) research policy.
During the Bush administration, hESC research was among the most
controversial of scientific research topics, and the federal government's role in
financing hESC research was limited both in scope and scale. Only certain
embryonic stem cell "lines" were eligible for federal research support. Federal
regulations prohibited the direct or indirect use of federal funds to finance
research using other stem cell lines, so that laboratory space or equipment
initially purchased with federal funds, for example, could not be used to support
research on ineligible stem cell lines. Congressional attempts either to restrict this
research further or to significantly expand the scope and scale of federal support
were unsuccessful.
In response to this deadlock in Washington, stem cell advocates turned to
state political systems-governors, legislatures, and bureaucracies-to continue
pursuing their agendas, with varying degrees of success. These efforts have
increased the amount of money devoted to hESC research and established
infrastructure-laboratory space, training programs, and the like-that was not
subject to federal spending restrictions. While both state and private funding have
been adversely affected by the recent recession and the sharp decline in the stock
market, states and private donors now spend more money than the federal
government to support hESC research.
Many observers expected a major break in the Washington gridlock over
stem cell research with the new administration. While a break has occurred, its
significance is difficult to assess. President Obama has recently fulfilled his
campaign promise to overturn executive orders that limited the scope and scale of
federal stem cell funding, but he has also left action on other significant stem cell
issues to the National Institutes of Health (NIH) and Congress.
This paper examines the current and likely future funding picture for hESC
* Rockefeller Institute of Government and Department of Public Administration and Policy,
University of Albany, State University of New York. Thanks to Courtney Asker for help with data
collection and thanks to Tom Gais for helpful comments on an earlier draft.
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research. It outlines the Bush administration's regulatory and funding policies,
inventories current state and private funding for stem cell research, and evaluates
the factors likely to shape future stem cell funding. My conclusions are
cautionary-while it seems likely that a new administration and Congress may
well harvest low-hanging legislative fruit that has already passed Congress by
substantial margins, the odds of a major shift in federal stem cell policy, at least
in the short run, are low. Many ethical and political issues surrounding stem cell
research remain controversial; furthermore, major problems with the national
economy, health care, wars in Iraq and Afghanistan, and recent problems in the
Middle East seem likely to consume much of the political attention and resources
available to both President Obama and Congress. The administration has also
committed to positions on other reproductive health issues which may complicate
political progress on stem cell questions. The recently enacted economic stimulus
package dramatically increases federal spending for biomedical research, but a
major increase in stem cell funding seems unlikely. What does seem likely, even
if state and private funding for stem cell research decline and federal funding
increases, is that most serious policymaking around stem cell research will
continue at the state level, rather than relocating to Washington.
I. STEM CELLS-EMBRYONIC AND OTHERS'
Stem cell research is a complex scientific and political undertaking in which
some aspects are extremely controversial and others are not. In the most general
sense, stem cells are undifferentiated "blank" cells that do not have a specific
physiological function, but which can, at least in theory, be turned into more
specialized cells that perform desired functions. The development of therapies
from these cells involves turning them into specialized types of cells that can
replace those damaged or destroyed by disease, namely cells that cannot be
replaced by natural processes. These specialized cells can then in turn be
developed into specialized tissues that can be used in the treatment of disease. If
stem cells can be turned into the specialized cells that produce dopamine, for
example, they can be used to replace cells that have been damaged by
Parkinson's disease.
Stem cell research uses a wide range of these types of cells, and only some
of them are controversial. Scientists use a variety of animal stem cells, both
embryonic and others, to study disease processes and to experiment with various
techniques that may eventually have applications in the treatment of human
disease-the techniques that were used to isolate human embryonic stem cells,
1. For a basic overview of stem cell research science, see INT'L SOC'Y FOR STEM CELL
RESEARCH, STEM CELL FACTS: THE NEXT FRONTIER? (2008), available at http://www.isscr.org/
public/ISSCR08_PubEdBroch.pdf; and International Society for Stem Cell Research, FAQ,
http://www.isscr.org/public/faq.htm (last visited Apr. 30, 2009).
IX:2 (2009)
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for example, were first developed in animal models. Research using animal stem
cells of different types is not controversial and has been routinely supported by
the NIH.
Research using human stem cells is more politically complex. So-called
"adult" stem cells, 2 which are typically irreversibly developed and more
specialized in that they can generally only be converted into a limited range of
more specialized cells, were initially isolated in the 1950s. These cells have come
to be used as part of treatment regimes for some diseases, particularly those that
require the replacement of the immune system. Hematopoietic stem cells, for
example, which can be isolated from bone marrow, are regularly used to
replenish the blood cells that are destroyed by treatments for leukemia and other
forms of cancer. Research using these types of stem cells, which occur naturally
in the body and can be isolated without any adverse effects, is not particularly
controversial and is regularly funded by NIH and other organizations that support
biomedical research.
By contrast, research using human embryonic stem cells has been extremely
controversial. These cells, which were isolated in the late 1990s, form during the
development of a fertilized human embryo and are extracted in the first few days
of the embryo's growth. These cells are, at least in theory, capable of being
turned into all of the body's specialized cell types and thus are potentially usable
to treat a broader range of diseases than more specialized (less flexible) adult
stem cells. The controversy surrounding research using these cells arises from the
fact that the extraction of the stem cells destroys the embryo, which many critics
find ethically unacceptable.3
Several recent scientific developments may allow the creation of stem cell
lines without the destruction of embryos.4 Most visibly, several groups have
developed "induced pluripotent stem cells" (iPSCs) by using genetic
manipulation to turn a skin cell into cells that closely resemble embryonic stem
cells.5 This ability to reverse the development of an existing cell and turn it into a
2. The term "adult" is confusing, since these cells do not necessarily come from chronological
adults. Some varieties of "adult" stem cells, in fact, can be isolated from the blood in the umbilical
cords of new born infants or the pulp under baby teeth. The use of the term "adult" comes from the
fact that these stem cells are found in tissue that has already developed.
3. But see PRESIDENT'S COUNCIL ON BIOETHICS, ALTERNATIVE SOURCES OF HUMAN
PLURIPOTENT STEM CELLS 24 (2005), available at http://www.bioethics.gov/reports/
white-paper/altemative-sources-white-paper.pdf (discussing techniques for removing cells from
"live" embryos in a process similar to pre-implantation genetic diagnosis).
4. See Rajesh Rao, Alternatives to Embryonic Stem Cells and Cloning: A Brief Scientific
Overview, 9 YALE J. HEALTH POL'Y L. & ETHICS 603 (2009).
5. M. William Lensch, Breakthroughs in Stem Cell Biology: Human iWS Cells, STEM CELL
BRIEFINGS (Int'l Soc'y for Stem Cell Research, Deerfield, Ill.), Feb. 27, 2008,
http://www.isscr.org/public/briefings/breakthrough.html. For a more detailed explanation, see
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stem cell, which may then be turned into an entirely different type of cell, has
become politically controversial. Detractors of hESC research have argued that
the availability of this and other alternative techniques to produce stem cell lines
lessens or eliminates the need to support research using hESCs. Many scientists
argue such a conclusion is premature, noting that iPSCs have not been
demonstrated to be acceptable substitutes for hESCs, which will remain the "gold
standard" for stem cell research for some time to come.6
II. FEDERAL REGULATION AND FUNDING
In spite of considerable public attention to stem cell-related issues over the
last fifteen years, there is little consensus about the appropriate scope and
financing for hESC research. 7 Debate in Washington has generally not addressed
the permissibility or legality of embryonic stem cell research, but it has rather
focused on the narrower question of which stem cell "lines" should be eligible to
receive federal financial support through the NIH and other federal agencies.
8
The Bush administration, together with some (though not all) religious and pro-
life groups, argued consistently that human embryos have the same moral status
as human life and that research destroying embryos should be restricted, if not
entirely prohibited. Many Democrats, together with disease advocacy groups and
some pro-life Republicans, have disputed this characterization of the moral status
of the embryo and have argued that hESC research presents considerable
potential for treating a wide range of diseases.
The use of federal funds to create, destroy, or harm embryos for research
purposes has been routinely prohibited in appropriations bills since the mid-
1990s through the so-called Dickey-Wicker Amendment. 9 Subsequent debate,
however, has relied on arguments that this prohibition does not extend to
Gretchen Vogel, Breakthrough of the Year: Reprogramming Cells, 322 SCIENCE 1766 (2008).
6. For a recent example of these competing positions, see Rob Stein, Researchers Find Safer
Way To Produce Stem Cell Alternative, WASH. POST, Mar. 2, 2009, at AS.
7. For a history of federal policy in this area, see PRESIDENT'S COUNCIL ON BIOETHICS,
MONITORING STEM CELL RESEARCH 21-52 (2004), available at http://www.bioethics.gov/reports/
stemcell/pcbe -final versionmonitoring-stem cell-research.pdf.
8. See e.g., Ceci Connolly, 2 GOP Senators Defend Bush on Stem Cell Research, WASH.
POST, Aug. 13, 2004, at A2; Rick Weiss, Approved Stem Cells'Potential Questioned, WASH. POST,
Oct. 29, 2004, at A3; Rick Weiss, Bill Renews Fight on Stem Cells, WASH. POST, Feb. 17, 2005, at
A6.
9. The original amendment can be found in the Balanced Budget Downpayment Act, Pub. L.
No. 104-99 § 128, 110 Stat. 26, 34 (1996) (affecting NIH funding for FY 1996 contained in Pub. L.
No. 104-91, 110 Stat. 7 (1996)). For subsequent fiscal years, the rider is found in Title V, General
Provisions, of the Labor, HHS and Education appropriations acts. See JUDITH A. JOHNSON & ERIN
D. WILLIAMS, CONGRESSIONAL RESEARCH SERV., CRS REPORT FOR CONGRESS: STEM CELL
RESEARCH 2 n.7 (2005), available at http://fpc.state.gov/documents/organization/51131 .pdf.
IX:2 (2009)
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research on stem cell lines created using other funding sources.' ° The Clinton
administration advocated an expansive view of this argument, which would have
encouraged researchers to fund the creation of stem cell lines from other sources
and then apply for federal funds to continue research on these "pre-existing"
lines."l The Bush administration, by contrast, largely limited federal funding
support to the small number of lines existing before 2001. The more recent
development of techniques for devising stem cell lines that do not require the
destruction of embryos led to an executive order signed in 2007, which expanded
eligibility to stem cell lines developed "without creating a human embryo for
research purposes or destroying, discarding or submitting to harm a human
embryo or fetus." 12 The NIH developed elaborate guidance for defining "harm"
to an embryo or fetus, but this executive order was revoked by President
Obama's recent order.13
The Bush administration also adopted an unusually restrictive policy that
prohibited the direct or indirect use of federal funds to support research on
ineligible stem cell lines. 14 In order to avoid jeopardizing their federal funds,
many universities and other research institutes found it prudent to build separate
labs and purchase completely separate equipment to be used in hESC research.
These facilities still draw on non-federal sources of funding, allowing research
institutes to avoid charges that they are using, for example, lab equipment
originally purchased with federal funds to indirectly support research on
ineligible stem cell lines. 15
Despite considerable effort, the federal policymaking process has not been
successful in moving hESC research policy in any particular substantive
direction. By one count, more than forty separate pieces of legislation have been
introduced since 2001 in this general area, ranging from attempts to prohibit or
10. See JOHNSON & WILLIAMS, supra note 9; George Q. Daley, Missed Opportunities in
Embryonic Stem-Cell Research, 351 NEw ENG. J. MED. 627 (2004).
11. See National Institutes of Health Guidelines for Research Using Human Pluripotent Stem
Cells, 65 Fed. Reg. 51,976 (Aug. 25, 2000) (guidelines under the Clinton administration).
12. Exec. Order No. 13,435, 72 Fed. Reg. 34,591 (June 20, 2007).
13. For details, see NAT'L INSTS. OF HEALTH, PLAN FOR IMPLEMENTATION OF EXECUTIVE ORDER
13435: EXPANDING APPROVED STEM CELL LINES IN ETHICALLY RESPONSIBLE WAYS (2007),
available at http://stemcells.nih.gov/staticresources/policy/eo13435.pdf. For an explanation of the
political context surrounding this executive order, see Rick Weiss, Future of Stem Cell Tests May
Hang on Defining Embryo Harm, WASH. POST, July 29, 2007, at A8. For the revocation of this
order, see Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
14. Roger G. Noll, The Politics and Economics of Implementing State-Sponsored Embryonic
Stem-Cell Research 20-21 (Stanford Inst. for Econ. Policy Research, Discussion Paper 04-28,
2005), available at http://www.stanford.edu/group/siepr/cgi-bin/siepr/?q=system/files/shared/
pubs/papers/pdf/04-28.pdf.
15. See, e.g., Claudia Driefus, At Harvard's Stem Cell Center, the Barriers Run Deep and
Wide, N.Y. TIMES, Jan. 24, 2006, at F2.
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even criminalize all cloning research to efforts to expand the scope and scale of
federal support for hESC research. 16 None of these initiatives has become law.
Congress twice passed, and President Bush twice vetoed, legislation that would
have expanded federal support to cell lines derived from embryos created, but not
used, for in vitro fertilization. 17 There are large numbers of these unused
embryos, most of which will likely be destroyed, currently being stored at
fertility clinics. The bills Congress passed would have allowed researchers to use
federal funds to develop stem cell lines from these embryos if the individuals
who deposited them donated them for research. The Dickey-Wicker Amendment
continues to limit federal funding for research that would entail the destruction of
embryos;1 8 however, current federal law imposes no restrictions on research
funded by private or other non-federal funds.
As a result of these funding limits, federal support for hESC research has
historically been small. Appendix A displays past and estimated funding levels
by the NIH for hESC research and other kinds of stem cell research for the last
six fiscal years. Total NIH funding for all kinds of stem cell research has
increased over this period by approximately twenty percent, from $553 million to
$938 million annually. Spending on hESC research, however, amounts to only
about nine percent of this total, or slightly less than $90 million annually. Other
forms of stem cell research that are not particularly controversial attract more
support and account for the bulk of growth in spending over this period. There
are no limits on other stem cell research activities of the sort that have been
attached to hESC research. Researchers have developed treatments using other
types of human stem cells, and many of the techniques used to isolate or
manipulate embryonic stem cells have been developed using animal cells. Direct
federal support to date for hESC research has been limited. As Appendix A
notes, spending for all forms of stem cell research is relatively small compared to
NIH support in such areas as cancer, genetics, biotechnology, and cardiovascular
research, and support for hESC research is roughly comparable to NIH spending
on Alzheimer's disease, diagnostic radiology, and eye diseases.
III. STATE ACTIONS AND FUNDING
While decisive federal action around hESC research has proven impossible
to date, more than a few states have been able to establish coherent state research
policies. As in numerous other areas, advocates frustrated by the deadlock in
16. FRANCIS FUKUYAMA & FRANCO FURGER, BEYOND BIOETHICS: A PROPOSAL FOR
MODERNIZING THE REGULATION OF HUMAN BIOTECHNOLOGIES 129 (2007).
17. See Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th Cong. (2006); Stem
Cell Research Enhancement Act of 2007, S. 5, 110th Cong. (2007).
18. Sheryl Gay Stolberg, New Stem Cell Policy To Leave Thorniest Issue to Congress, N.Y.
TIMES, Mar. 9, 2009, at Al.
IX:2 (2009)
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Washington have been able to move their agendas forward at the state level.
While policymakers in many states have avoided becoming involved in the
complex and controversial issues surrounding hESC research, others have been
able to construct majorities around particular approaches to this research. Like
the legislation proposed but not enacted at the federal level, the legislation
actually enacted by states has been extremely diverse in scope and intent. These
state laws range again from legislation to prohibit and even criminalize hESC
research to active encouragement of hESC research inside state borders and
authorization of considerable amounts of state funds to support it.19 At the time
of this writing, five states ban or restrict hESC research,2° while as many as ten
have supported it in some form.21
State financial support for stem cell research is particularly significant
because few states have any experience with supporting biomedical research on a
large scale. While some states have supported various kinds of targeted research
initiatives at state universities to encourage other types of technology, almost no
states have experience with operating competitive, peer-reviewed research
programs in medicine or genetic research. Funding from the NIH and other
federal agencies has been ubiquitous in biomedical research, so states have not
previously felt compelled to support research in these areas.
In spite of this limited experience, several states have approved, and more
have proposed, substantial spending from state sources to support stem cell
research. A summary of state activity to date is presented in Appendix B. There
is no authoritative source of comparable data on state spending on stem cell
research, and it is frequently difficult to use publicly available information to
19. For an excellent recent review of state activities, see generally Aaron D. Levine, Policy
Considerations for States Supporting Stem Cell Research: Evidence from a Survey of Stem Cell
Scientists, 68 PUB. ADMIN. REv. 681 (2008). Current and pending state legislation on these issues
can be tracked at National Conference of State Legislatures, Stem Cell Research,
http://www.ncsl.org/programs/health/genetics/embfet.htm (last visited Apr. 30, 2009).
20. These states are Arkansas, Indiana, Louisiana, North Dakota and South Dakota. See
Dahleen Glanton, A Stem Cell Battle Along State Lines, L.A. TIMES, Mar. 13, 2009, at A21,
available at http://www.latimes.com/news/nationworld/nation/la-na-stemcells-states 13-2009mar
13,0,773884.story; see also National Conference of State Legislatures, supra note 19 (listing states'
restrictions on research with embryos and fetuses). Other states have begun considering enacting
legislation in the wake of Executive Order 13,505. See Shaila Dewan, After Change in Federal
Policy, Some States Take Steps To Limit Stem Cell Research, N.Y. TIMES, Mar. 13, 2009, at A9,
available at http://www.nytimes.com/2009/03/14/us/politics/I4stem.html.
21. These states are California, Connecticut, Illinois, Maryland, Massachusetts, Minnesota,
New Jersey, New York, Ohio, and Wisconsin, as I will discuss here. For a continually updated
listing of state activities related to stem cell research, see National Conference of State Legislatures,
supra note 19 (noting additional support for adult stem cell but not embryonic stem cell research in
Indiana and Virginia and activities by Washington that may enable future funding of stem cell
research).
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apportion various forms of state spending between hESC research and other
forms of stem cell research.
By far the largest state initiative to date has been in California. In 2004,
California voters approved an initiative to spend $3 billion, financed by state
general obligation bonds, over a period of ten years to support stem cell research.
The California Institute for Regenerative Medicine (CIRM), the agency that
manages the state's stem cell program, has already allocated over $600 million in
hESC research support, or more than five times what NIH is allocating annually
to these activities.22
Other state allocations to date have been smaller. Ohio and Minnesota have
made "one time" appropriations for adult stem cell research and capital
construction, respectively. New Jersey, Illinois, and Connecticut have allocated
research grants of varying sizes, and New Jersey has also approved funds for the
construction of a stem cell laboratory, although a bond issue to support an
ongoing research program was defeated in 2007.23 Connecticut has approved
ongoing support for stem cell research programs from tobacco settlement
revenues, 24 and Maryland has made multiple awards supported by general state
revenues. Wisconsin has not made separate appropriations of state funds to
support hESC research, but the state has been aggressively promoting stem cells
as an economic development strategy.26 University of Wisconsin is a major
center for hESC research-the university is one of the places where hESCs were
first isolated in the late 1990s-and the state holds important patents in hESC
technology. The university also houses the National Stem Cell Bank, established
22. See California Institute for Regenerative Medicine, Welcome, http://www.cirm.ca.gov (last
visited Apr. 30, 2009) (detailing the California funding allocation and CIRM approval of more than
$693 million in grants to date).
23. For a description of the bond issue's defeat, see Richard G. Jones & Kareem Fahim, Bid
for Stem Cell Financing Was Late and Lukewarm, Organizers Concede, N.Y. TIMES, Nov. 9, 2007,
at B 1, available at http://www.nytimes.com/2007/11/09/nyregion/09abort.html.
24. The enabling legislation (Connecticut Public Act 05-149; Senate Bill 934) appropriated
$20 million from state general funds to support the first two years of research grants and also
authorized the transfer of $10 million annually from the state Tobacco Settlement Fund to the
state's Stem Cell Research Fund for the next eight years (fiscal years 2008 to 2015). See 2005
Conn. Legis. Serv. No. 05-149 (West) (codified as amended at CoN. GEN. STAT. ANN. §§ 19a-32d
to -32g (West 2006)); Connecticut Department of Public Health, Stem Cell Research Program -
About CT's Program, http://www.ct.gov/dph/cwp/view.asp?a=3142&Q=389690 (last visited Apr.
30, 2009).
25. For details on funding and financial resources for the Maryland program, see Maryland
Stem Cell Research Fund, About Us, http://www.mscrf.org/content/aboutus/index.cfm (last visited
Apr. 30, 2009).
26. For a brief description of these efforts, see Press Release, Office of the Governor,
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by NIH to maintain and distribute many of the stem cell lines that could be
researched using federal funds.27
Larger state stem cell programs are in the works. The FY 2008 New York
State budget appropriated $100 million in state funding to establish a stem cell
research program, and there are plans for additional funding, although the
potential source remains unclear.28 The state has made two rounds of awards, has
issued a strategic plan, and is soliciting applications for other funding.
Massachusetts recently passed a $1 billion life sciences initiative that includes an
indeterminate amount for stem cell research. 29 Both states are major centers for
hESC research, and there appears to be significant bipartisan political support for
ongoing state funding. Both states have also taken care to spread initial spending
broadly in terms of geography, thereby maximizing the number of areas and
legislative districts with an economic stake in continued funding.
At least some of these state initiatives appear to be sustainable into the
Obama administration. California's Proposition 71 authorized the disbursement
of $3 billion in research funds over ten years, and CIRM management has begun
to lobby for additional funding sources past this time horizon.30 Connecticut has
earmarked $100 million in state funds over a decade. Existing programs in New
York and Massachusetts also contemplate ongoing funding for stem cell
research. Although the New Jersey bond issue to support stem cell research was
defeated, the state's governor has discussed plans to support this research by
other means, and the state has made small economic development grants to
biotech firms interested in stem cell therapies.31 Maryland, by contrast, relies on
annual state appropriations to support stem cell research. While annual
appropriations are less reliable than earmarked bond proceeds, strong political
support may produce stable funding. Recent budget problems may have reduced
the size of programs in some states, but there is no evidence as yet that states are
abolishing stem cell programs in response to financial difficulties. There have
27. President Obama's executive order has now removed many line-based restrictions on
federal funding for hESC research. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
28. See EMPIRE STATE STEM CELL BD., STRATEGIC PLAN 14 (2008), available at
http://stemcell.ny.gov/docs/NYSTEM-Strategic-Plan-FINAL.pdf.
29. For a description of the Massachusetts initiative, see the website of the Massachusetts Life
Sciences Center, the state agency which directs the program. The Massachusetts Life Sciences
Center, http://www.masslifesciences.com/mission.html (last visited Apr. 30, 2009).
30. These efforts include pursuing funding from the Obama administration's economic
stimulus plan and private placement of state bonds. For details, see the ongoing coverage in the
California Stem Cell Report blog. California Stem Cell Report, http://califomiastemcell
report.blogspot.com (last visited Apr. 30, 2009).
31. Alex Philippidis, Corzine To 'Revisit' Stem-Cell Referendum as Calif Company Expands
to New Jersey, BIOREGION NEWS, May 5, 2008, http://www.genomeweb.com/bioregionnews/
corzine-%E2%80%98revisit%E2%80%99-stem-cell-referendum-calif-company-expands-new-
jersey (free subscription required for access).
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been public complaints about the failure of state programs to yield tangible
results and a variety of issues raised about program management, particularly in
California, but there have been no serious political challenges as yet to these
programs' continued existence.32
Several states have begun to shift the form of support they offer away from
research-oriented grants to universities and towards support of for-profit
companies aimed at product development. California has recently awarded its
first substantial grants to private companies 33 and is in the process of developing
a loan program targeted at biotechnology companies involved in the development
of stem cell therapies.34 The Massachusetts Life Science Center, whose mandate
includes support for stem cell research, has funded no stem cell activities to date
beyond a registry of stem cell lines and a stem cell "bank." The Center's only
"round" of funding to date, which did not involve any stem cell projects,
supported joint projects by universities and private companies. This pattern
suggests that further state support for stem cell research, when it comes, may be
more "applied" or "translational" in nature rather than aimed at university-based
research. 3
In addition to providing significant financial support for stem cell research
not eligible for federal funding, these state initiatives also have established
centers of policymaking for stem cell research independent of federal influence.
States that have established funding programs for stem cell research have been
compelled to develop regulations governing the types of research that will be
supported, acceptable sources and payment for stem cell lines to be used in
funded research, intellectual property, an acceptable "return" to state
governments on their research investment, and a variety of other complex issues.
While most states appear to have relied heavily for many of these issues on
model guidelines promulgated by the National Academy of Sciences and the
International Society for Stem Cell Research,36 state policies differ substantially.
32. See, e.g., Thomas Lee, Stem Cells: Time to Make Good on Promises, MINNEAPOLIS STAR
TRIB., Sept. 28, 2008, at ID, available at http://www.startribune.com/business/29828789.html;
Bernadette Tansey, Obama Policy a Liftfor Stem Cell Researchers, S.F. CHRON., Nov. 29, 2008, at
A I, available at http://www.sfgate.comL/cgi-bin/article.cgi?f-/c/a/2008/11/29/MN76147PBR.DTL.
33. Business Snags $5.3 Million from CIRM, California Stem Cell Report, Dec. 15, 2008,
http://californiastemcellreport.blogspot.com/2008/12/business-snags-53-million-from-cirm.html.
34. $500 Million CIRM Lending Program Up on Wednesday; Details Missing, California Stem
Cell Report, Jan. 18, 2009, http://califomiastemcellreport.blogspot.com/2009/01/500-million-cirm-
lending-program-up-on.html.
35. See Ben Butkus, Massachusetts LSC Awards $3.7M to Spur Public-Private R&D
Partnerships, BIOTECH TRANSFER WEEK, Dec. 31, 2008, http://www.genomeweb.com/
biotechtransferweek/massachusetts-sc-awards-37m-spur-pubic-private-rd-partnerships.
36. The National Academy guidelines are contained in COMM. ON GUIDELINES FOR HUMAN
EMBRYONIC STEM CELL RESEARCH, GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH
(2005), available at http://www.nap.edu/openbook.php?isbn=0309096537, with amendments
IX:2 (2009)
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Some states restrict eligibility for funding to universities and other nonprofit
research institutes, for example, while others contemplate grants to for-profit
companies or consortia of companies and universities. Some state regulations
prohibit the use of state funds to pay donors of eggs that will be used in
developing stem cell lines; others require only assurances that the donation of
eggs has been voluntary. While the potential for conflict between the policies of
different states may complicate attempts for researchers to collaborate across
state lines, several states have established a consortium (the Interstate Alliance on
Stem Cell Research) to identify and ameliorate such conflicts.37 The existence of
state laws and regulations (or, in the case of California, covenants with
bondholders) governing the expenditure of state funds for stem cell research may
complicate any federal efforts to expand regulation of this research beyond those
projects supported with federal funds.
A second reason for expecting state stem cell programs to persist is that they
appear to have been effective tools for state economic development. Levine's
recent work suggests that state funding and permissive state policies that place
few limits on stem cell research have been effective in creating awareness among
stem cell scientists of differences among states, causing permissive states to be
seen as more attractive research environments.38 Some states have been
aggressively recruiting scientists from other states, which may continue to
generate demands for support from medical schools and other institutions fearful
of losing productive researchers.
IV. PRIVATE PHILANTHROPY AND STEM CELL RESEARCH
A second major source of funding for hESC research and other forms of
stem cell research has been private philanthropy. While private support, even on
a large scale, to support biomedical research is nothing new, private support for
stem cell research in general, and hESC research in particular, has been unusual
in two ways: it is large relative to the scale of the research enterprise and the
level of federal support, and it has been used for a broader array of activities than
has been typical.
While a comprehensive accounting of private contributions to stem cell
research is impossible, a listing of some recent large, visible gifts is provided in
Appendix C. This list is incomplete. Many national foundations which finance
issued in 2007 and 2008. The International Society for Stem Cell Research guidelines are contained
in INT'L SOC'Y FOR STEM CELL RESEARCH, GUIDELINES FOR THE CONDUCT OF HUMAN EMBRYONIC
STEM CELL RESEARCH (2006), available at http://www.isscr.org/guidelines/ISSCRhESC
guidelines2006.pdf.
37. For details, see the Alliance's website at Interstate Alliance on Stem Cell Research,
Welcome, http://www.iascr.org/ (last visited Apr. 30, 2009).
38. Levine, supra note 19.
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research into particular diseases, such as the Juvenile Diabetes Research
Foundation, the Michael J. Fox Foundation for Parkinson's Research, and the
Leukemia and Lymphoma Society, fund stem cell research projects; other
foundations and donors may also fund stem cell projects at individual
institutions. The overall size of these donations is difficult to identify, although a
Wall Street Journal article has claimed that private funding constitutes the
primary source of support for hESC research. 39 This list also excludes investment
by private companies and venture capital funds for stem cell-related projects.
One published estimate places venture capital investment in stem cell companies
of all types at $1.1 billion between 1995 and 2007, a modest amount by venture
capital standards. 40 This investment is almost certainly focused on products
developed from adult stem cells, which have not been as controversial as
embryonic stem cells. More recent anecdotal reports suggest that venture capital
investment in adult stem cell companies may have accelerated as more products
are developed, although many of these products are at the pre-clinical trial
stage.41
While this list is incomplete, it reports gifts totaling some $2.7 billion, a
large amount given the current scale of federal funding and the overall size of the
stem cell research enterprise. Itemizing the activities that these funds are intended
to support, separating support for hESC research from other stem cell research
funding, or identifying the time period over which these funds are to be spent is
impossible with any degree of precision. It seems reasonable, however, to infer
that much of this funding, particularly to institutions in California,
Massachusetts, New York, and Maryland that are already major centers of hESC
research, goes to support hESC research in various ways. Contributions to
establish stem cell research centers at particular universities are common, which
may mean that these funds support the acquisition of lab space and equipment,
salaries for key center personnel, and other "overhead" or "start-up" functions as
well as activities more directly related to biomedical research. The Harvard Stem
Cell Institute, for example, has developed several hESC "lines" that are available
to other researchers in addition to supporting its own research program.42 The
39. Robert J. Hughes, Stem Cell Funding's Private Side, WALL ST. J., July 28, 2006, at W2.
40. Lee, supra note 32 (citing an estimate by MoneyTree, Inc.).
41. See, e.g., Chuck Soder, Stem Cell Progress Aiding Firms' Product Commercialization
Plans, CRAINS CLEVELAND Bus., Jan. 5, 2009, at 1; John Sterling, Toucan Capital Holds Largest
Portfolio of Stem Cell and Regenerative Medicine Companies, GENETIC ENGINEERING &
BIOTECHNOLOGY NEWS, Jan. 23, 2009, http://www.genengnews.com/news/bnitem.aspx?name
=48528449. For examples of products that have been through initial clinical trials, see Amy
Coombs, Stem Cells for the Heart, a New Wave of Clinical Trials, NATURE REP. STEM CELLS, Apr.
10, 2008, http://www.nature.com/stemcells/2008/0804/0804 I 0/full/stemcells.2008.55.html.
42. See Approval Granted for Harvard Stem Cell Institute Researchers To Attempt Creation of
Disease-Specific Embryonic Stem Cell Lines, HARV. U. GAZETTE, June 6, 2006,
IX:2 (2009)
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largest gifts in this Appendix, however, are donations of stock to the Stowers
Research Institute in Missouri that cannot be allocated easily to any particular
activity.43
One novel trend, at least in California, is the use of private money to directly
support the activities of government agencies. CIRM management actively
solicited donations amounting to some $18 million from private parties to pay the
organization's initial operating expenses, and the agency will occupy office space
in downtown San Francisco rent- and utility-free for a decade as a result of
44private contributions. Private donors also supported CIRM's research program
through the purchase of low interest Bond Anticipation Notes,45 which were
repaid once the bond issue authorized by Proposition 71 was sold. A similar use
of private placements has been suggested as a possible means of coping with the
state of California's suspension of bond issues to address extremely severe
budget problems.46 The Massachusetts proposal for state support of stem cell
research also includes $250 million in private matching funds to be used in
conjunction with state funding.47
The sustainability of private donations at this level to support stem cell
research in general and hESC research in particular is unclear. Many disease
foundations support stem cell research, including hESC research, as part of their
http://www.hno.harvard.edu/gazette/daily/2006/06/06-stemcell.html.
43. The Stowers situation is complicated. As described in Institute publications, "far more" of
the Institute's research program to date has involved adult and germ-line stem cells than embryonic
stem cells. Institute management has attempted to expand its embryonic stem cell research
program, but persistent attempts by the Missouri legislature to restrict or criminalize this research
has made it difficult to attract researchers to the Institute's Kansas City campus. In response to the
ongoing political debate in Missouri, the Institute has funded embryonic stem cell research
underway at Harvard, which is listed in Appendix B, moved significant endowment assets from
Missouri to a Delaware-based non-profit organization, and has recently announced it is putting
further expansion plans in Missouri on hold until the political environment stabilizes. See William
B. Neaves, Why the Stowers Institute Supports Stem Cell Research, STOWERS REP., Fall 2006, at 2,
2; Stephanie Simon, Stem Cell Dissent Roils States, L.A. TIMES, Aug. 1, 2007, at A12; Rob
Roberts, Stowers Puts Expansion Plans on Hold, KANSAS CITY Bus. J., Jun. 28, 2007,
http://kansascity.bizjoumals.com/kansascity/stories/2007/06/25/daily37.html.
44. David Hamilton, Donors Sustain Stem Cell Effort in California Amid Funding Battle,
WALL ST. J., Aug. 16, 2006, at Al.
45. See Karen Gullo & Rob Waters, California's $3 Bln Stem Cell Bonds Approved by Judge,
BLOOMBERG.COM, Apr. 21, 2006, http://www.bloomberg.com/apps/news?pid=l00000l3&sid=aF7
GZ7xaVaoY&refer-us.
46. For details, see Ron Leuty, State's Budget Crisis Could Strain Stem Cell Research Efforts,
SILICON VALLEY/SAN JOSE Bus. J., Dec. 19, 2008, http://sanjose.bizjoumals.com/sanjose/stories/
2008/12/22/story.html?jst=pnpnk.
47. Commonwealth of Massachusetts, Massachusetts Life Sciences Initiative Strategy,
http://www.mass.gov/Agov3/docs/masslife sciences-strategy.rtf (last visited Apr. 30, 2009).
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ongoing research funding activities, and total hESC research funding from this
source may well exceed funding by the federal government. While disease
foundations typically do not report funding amounts for stem cell or any other
particular line of research in their annual reports or financial statements, the
Juvenile Diabetes Research Foundation, one of the larger disease foundations, by
itself spent approximately $4.9 million in FY 2008 on hESC research.48 Even if
support from other individual disease foundations is smaller, it would not be
difficult for total foundation support to exceed federal funding. As noted in
Appendix C, several universities have also established large fundraising
campaigns to support hESC and other stem cell research, which may be
successful to some degree in establishing a stable flow of funds for individual
campuses. In addition, the recent decline in the stock market may have
significantly reduced the net worth of many foundations and lessened their ability
to continue to support research at this level. While there may be fewer large
grants to establish new research programs or build labs independent of the
current NIH funding restrictions, there may be enough ongoing support for
foundations and other private donors to continue to outspend NIH on hESC
research.
While a conclusive accounting appears impossible, the available evidence
strongly suggests that both state governments and private foundations are
outspending the federal government in the support of hESC research and have
become major policymakers around stem cell research. California has been
particularly active in this regard: the state is currently the largest supporter of
hESC research in the world and has been actively seeking collaborative
relationships with funding agencies in other countries. Because the federal
government has limited its support of stem cell research, it has exercised
significantly less influence in stem cell research policy than in other scientific
areas. Some observers have suggested that this regulatory picture may change
with the Obama administration and a new Congress. I now turn to an
examination of the likely future of hESC research policy and funding.
V. OBAMA'S EXECUTIVE ORDER AND THE OUTLOOK FOR STEM CELL FUNDING
Some observers expected this picture to change dramatically with a new
administration and a new Congress. 49 The picture has clearly changed, but it is
48. Juvenile Diabetes Research Foundation, Stem Cell Facts, http://advocacy.jdrf.org/
files/GeneralFiles/Advocacy/2009/Stem-Cell Therapies.pdf (last visited Apr. 30, 2009); see also
Hughes, supra note 39.
49. See, e.g., Carl Hulse, Democrats Weigh Methods To End Stem Cell Ban, N.Y. TIMES, Jan.
3, 2009, at A 11; Gautam Naik & Robert Lee Hotz, Obama's Promise on Stem Cells Doesn't
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still uncertain how dramatic the change will prove to be. After some pressure
from advocates, President Obama recently signed an executive order that
repealed the Bush administration's restrictions on the stem cell lines that federal
funding can be used to support, eliminated the requirement that federally
supported research be segregated from that on ineligible lines, and revoked
Bush's recent executive order allowing federal support for research only on lines
created by means that did not destroy or harm an embryo.5° The order was,
however, narrowly drawn and articulated no particular standards to govern the
origins of lines that would qualify for federal funds. The only standard referenced
in the order is "to the extent permitted by law." To fill this gap, the NIH were
directed to issue "guidance on such research" within 120 days.5' The President
has not called for the abolition of the Dickey-Wicker amendment, and his chief
domestic policy advisor has been quoted to the effect that the administration will
52have no position on the issue. In similar fashion, the administration has not
called explicitly for an expansion of funding for embryonic stem cell research
and has not endorsed more controversial means of producing embryonic stem
cells such as somatic cell nuclear transfer.53
This failure on the part of the President to endorse any particular standard
for stem cell lines, the transfer of responsibility for promulgating standards to
NIH (thus effectively delaying a decision on the administration's stem cell
policy), and the staging of the event at which the order was signed provide
circumstantial evidence for the prediction that the administration is unlikely to
seek more than incremental change in stem cell policy in the short run. The event
was announced at a time when it was unlikely to attract major media attention,
and the signing of the executive order was coupled with the signing of a
presidential memorandum on scientific integrity rather than being the sole subject
of the presidential appearance. The President's statement at the signing took
some care to acknowledge opposing views on stem cell research and promised
"strict guidelines, which we will rigorously enforce" in the conduct of stem cell
research. 14
50. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
51. For an explanation, see Rob Stein, Obama 's Order on Stem Cells Leaves Key Questions to
NIH, WASH. POST, Mar. 10, 2009, at Al, available at http://www.washingtonpost.com/wp-
dyn/content/article/2009/03/09/AR2009030903156.html.
52. See Stolberg, supra note 18.
53. Somatic cell nuclear transfer is a technique in which the nucleus of a fertilized egg is
replaced with the nucleus of a somatic cell from a potential patient and then allowed to develop to
the point where stem cells can be collected. It has the potential virtue of producing cells and tissues
that are compatible with the patient's body and will not be attacked by the patient's immune
system. For details, see Richard Mollard, Somatic Cell Nuclear Transfer (SCNT) or Therapeutic
Cloning, International Society for Stem Cell Research, http://www.isscr.org/public/
therapeutic.cloning.pdf (last visited Apr. 30, 2009).
54. Transcript: Obama's Remarks on Stem Cell Research, N.Y. TIMES, Mar. 9, 2009,
15
Fossett: Beyond the Low-Hanging Fruit
Published by Yale Law School Legal Scholarship Repository, 2009
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
These circumstances suggest that the administration policy and the NIH
guidelines, when they appear, are likely to focus on incremental modifications to
existing policy. Perhaps the most obvious candidate for such changes would
involve standards proposed in bills which Congress has already passed twice
which expand the number of stem cell lines eligible for federal financial
support.5 5 These standards would expand eligible lines to include cells derived
from embryos initially created but no longer needed for reproductive purposes,
which would otherwise have been destroyed; these embryos will need to have
been donated under appropriate standards for informed consent.
While the elimination of the Bush administration's restrictions and
expansion of eligible lines along the lines Congress has already approved are not
trivial, these changes will not directly expand federal support for stem cell
research of any sort or significantly expand the heretofore limited federal role in
the governance of this research. It is uncertain, however, whether the
administration and its congressional allies will seek more than incremental
changes in stem cell funding or substantial legislative changes that would
significantly alter the existing decentralized stem cell governance structure. It
might be argued that there are substantial reasons for the Obama administration,
and for stem cell allies more generally, not to push for more serious changes in
federal stem cell policy in the short run.
Perhaps the most obvious reason for not pursuing more dramatic change in
stem cell policy is the demand for political capital and attention from other
equally or more pressing problems. The Obama administration and new Congress
have inherited wars in Iraq and Afghanistan, flare-ups in the Middle East,
extremely expensive and divisive ongoing repairs to the country's financial
system and overall economy, controversial anti-terrorism policies, and increasing
problems with health care coverage and global warming, among other
difficulties. Dealing with these issues, which are more or less mandatory items on
the national agenda, is likely to prove protracted and controversial, making it
possible that a new Congress and President simply will not have the time or
energy to address the complex, controversial, but non-crisis issues associated
with significantly altering the federal role in stem cell research. An executive
order or legislation of the scope described above would address issues that have
already been discussed and debated at some length before being passed twice by
http://www.nytimes.com/2009/03/09/us/politics/O9text-obama.html (not published in the print
edition).
55. See supra note 17. As this Article was going to press, NIH issued draft guidelines
expanding the number of stem cell lines eligible for federal funding along the lines suggested here.
After a period of public comment, final guidelines will be issued in the summer of 2009. Draft
National Institute of Health Guidelines for Human Stem Cell Research Notice, 74 Fed. Reg. 18,578
(proposed Apr. 23, 2009). For an explanation of the political context, see Ceci Connolly,
Compromise Rules Issued on Embryonic Stem Cells, WASH. POST, Apr. 18, 2009, at A4.
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Congress. While likely to attract strenuous protest from stem cell detractors, this
particular set of changes already has a pre-existing majority that has determined
that supporting it is in its political interest. Other changes have not received this
level of prior attention from the political process and may well be more
controversial and harder to resolve, raising the real possibility that a stem cell
reform bill could become gridlocked in Congress.
Several other factors contribute to the likelihood of congressional gridlock
around stem cell research. One is that a number of important issues around this
research remain politically controversial, and a congressional majority in favor of
reform cannot be assumed. The last two congressional elections have produced
significant Democratic majorities in both the House and the Senate, but many
Democratic gains have been in districts and states traditionally held by
Republicans, which means that the Democrats newly occupying these seats may
have to worry about electorates who are more dubious about the benefits of stem
cell research than those from traditionally Democratic areas. The Dickey-Wicker
amendment has been attached to every Department of Health and Human
Services appropriations bill since 1996,56 but there has been little serious
discussion of this restriction and no serious attempt to abolish it. There is no
ready-made majority for eliminating this restriction, as there may be for
expanding the number of stem cell lines eligible for federal funding.
Beyond debate over funding research involving the destruction of embryos,
controversy exists over the question of payment for eggs. Infertile couples are
currently allowed to offer payment for others' eggs for use in reproductive
therapies, but payment for eggs for research purposes is currently illegal in most
states (although payment for expenses and lost wages is sometimes
permissible).57 Researchers and advocates have increasingly complained that the
lack of embryos from which to extract stem cells constitutes a major barrier to
research progress and that efforts to solicit donations of eggs have largely proved
unsuccessful. Legislative efforts to allow the use of federal funds to pay egg
donors, however, are likely to prove quite controversial with at least some
groups. Interested parties particularly include women's health advocacy groups
that support stem cell research, but express strong concern about the risks
associated with egg extraction procedures and the vulnerability of lower-income
women to offers of significant amounts of cash.58
56. See JOHNSON & WILLIAMS, supra note 9, at 2 n.7.
57. For further details and a listing of state restrictions on the purchase or sale of human tissue,
see National Conference of State Legislatures, supra note 19.
58. See, e.g., The Implementation of Proposition 71, the Stem Cell Research and Cures Act:
Joint Informational Hearing of the S. Subcomm. on Health, S. Subcomm. on Stem Cell Research
Oversight, and the Assembly Comm. on Health, 2005 Leg., 2005-2006 Sess. 74 (Ca. 2005)
(statement of Francine Coeytaux, Pro-Choice Alliance for Responsible Research), available at
http://senweb03.senate.ca.gov/committee/standing/health/PROP 71_OVERSIGHTTRANSCRIP
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Proposals to expand federal control over stem cell research to projects not
supported by federal funds are also likely to prove controversial. NIH has no
experience with research oversight on the scale required to enforce uniform
federal guidelines, and federal rules might well conflict with state laws,
regulations, and, in the case of California, covenants with bondholders. Some
scientists have supported an expanded NIH role in the oversight of stem cell
research while others have argued that the combination of local, state, and federal
agency oversight currently in place is sufficient to ensure adequate attention to
outstanding scientific, ethical, and legal questions. 9
Proposals to dump a lot of additional federal money into stem cell research
may be similarly divisive. While the recently enacted economic stimulus package
contains increased funding for NIH as a whole, it seems unlikely that this
increase will produce anything more than incremental funding for stem cell
research, particularly hESC research. Opposition will come from the same groups
that have opposed this research all along and will likely even come from
elsewhere in the scientific community. After doubling between 1999 and 2003,60
NIH's overall budget has remained flat and even declined in real terms in recent
years. 6 1 As a result of these financial pressures, overall grant success rates have
fallen from thirty percent to less than twenty percent, and as low as ten percent in
some fields.62 Scientists who are having trouble supporting their own research
are likely to protest vehemently if their stem cell colleagues, who already receive
money from states and private foundations, now get additional support from NIH
as well. Funding for stem cell research in general, or hESC research in particular,
does not have a separate budgetary identity inside NIH, but is scattered across the
separate budgets of the NIH's component institutes that fund research on a range
of different diseases. NIH officials in some of these institutes may find it more
sensible to steer new funding away from stem cell research to other research
areas that do not have substantial state or private foundation support. The odds of
T.doc; Judy Norsigian, Egg Donation for IVF and Stem Cell Research: Time To Weigh the Risks to
Women's Health, DIFFERENT TAKES, Spring 2005, at 1, available at http://www.sc.edu/
healthycarolina/pdf/risksofeggdonation.pdf (statement by the Executive Director of Our Bodies
Ourselves);.
59. See Michael Warner & Hans Smith, Oversight from Bench to Bedside, Sci. PROGRESS,
Aug. 25, 2008, http://www.scienceprogress.org/2008/08/oversight-from-bench-to-bedside.
60. National Institutes of Health, The NIH Almanac - Appropriations, http://www.nih.gov/
about/almanac/appropriations/part2.htm (last visited Apr. 30, 2009).
61. Id. (showing that from 2003-2007 the NIH budget increased $196 million, while keeping
pace with inflation would have required an increase of $221 million).
62. For reviews of NIH's recent funding problems, see David Kom et al., The NIH Budget in
the "Postdoubling" Era, 296 SCIENCE 1401 (2002); Joseph Loscalzo, The NIH Budget and the
Future of Biomedical Research, 354 NEW ENG. J. MED. 1665 (2006); David G. Nathan & Alan N.
Schechter, NIH Support for Basic and Clinical Research: Biomedical Researcher Angst in 2006,
295 JAMA 2656 (2006).
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a lot of additional federal money being devoted to stem cell research seem low.
Even if NIH is able to expand support for stem cell research incrementally, it will
only be one payer among many, and not even the largest one.
A final factor complicating the prospects for non-incremental changes in
federal stem cell policy is continued scientific uncertainty around important
questions. One is the availability of alternative procedures, such as the
production of induced pluripotent stem cells (iPSCs) for producing embryonic
stem cell lines that do not require the destruction of embryos. The existence of
alternatives to hESCs would make stem cell research much less controversial, but
as discussed earlier in this Article, most stem cell scientists appear unconvinced
that iPSCs are reliable substitutes. 63 While studies comparing the two are
underway in several places, it seems unlikely that the political controversy
around hESCs will be resolved anytime soon, particularly if iPSCs prove to be
less than optimal replacements for hESCs.
Another scientific uncertainty with political consequences is the outcome of
the first clinical trial of a product derived from hESCs. Almost immediately after
President Obama's inauguration, the Food and Drug Administration approved an
application from Geron, a California company, to begin a Phase I clinical trial of
a hESC-based therapy for severe spinal cord injuries.64 Phase I trials are only
intended to gauge treatment safety, and the Geron trial will only include eight to
ten patients, but it might be expected that both stem cell detractors and supporters
will attempt to use the results of this trial as ammunition to support their
respective positions. In short, there are both political and scientific reasons to
expect incremental, rather than far-reaching, changes in federal stem cell policy
and funding over the short term.
Even if stem cell supporters are successful in expanding federal hESC
funding, it seems unlikely that states will diminish their funding efforts. As noted
above, many states have legally obligated funds with an extended time horizon,
over which it may be difficult to divert funds from their intended uses. If the NIH
funding picture remains tight, scientists and universities in some states may push
to institutionalize or expand state stem cell programs as an alternative source of
research funding. A second factor that is likely to encourage states to persist is
competition both among states and between states and several foreign countries
that have begun stem cell initiatives of their own. States see themselves, at least
rhetorically, as competing with one another for jobs, tax revenue, economic
development, and in the case of hESC research, research talent and prestige.
After the passage of Proposition 71 in California, much of the public rhetoric in
support of state funding for hESC research has focused on the need for states to
63. See, e.g., Hulse, supra note 49.
64. See Andrew Pollack, F.D.A. Approves a Stem Cell Trial, N.Y. TIMES, Jan. 23, 2009, at Bi,
available at http://www.nytimes.com/2009/01/23/business/23stem.html.
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remain "competitive" and to attract or retain scientific talent and prestige.
There is evidence that state efforts to make themselves more attractive to
stem cell researchers through permissive rules and funding have been
successful. 66 A recent report from the California Institute for Regenerative
Medicine, the state agency that manages the state's stem cell initiative, claims
that at least forty-five senior scientists have relocated to California from
elsewhere, 67 and there is some systematic evidence that stem cell researchers
have recently received more job offers than other types of scientists.68 The
Republic of Singapore, among other countries, has also mounted a highly
publicized stem cell program of its own, which has recruited American and other
scientists with subsidized lab space, ready access to stem cell lines, and other
inducements.69 While it is easy to overstate the effectiveness of such efforts, it
seems clear that many state politicians have found concerns over "brain drains"
to California or other more congenial locations to be effective arguments in
pressing for state support for hESC and other forms of stem cell research.
CONCLUSION
What seems most likely, in short, is that the immediate future will be like the
recent past, with the federal government being a relatively minor player and
states and private funders continuing to carry the major funding and policy
development burdens. hESC research will continue to be heavily supported in
some states and illegal in some others, with states weighing in with hESC
research funding programs of widely varying sizes. Competition among states is
good for hESC research supporters-more governors and gubernatorial
candidates may find it in their political interest to support state financing for this
research if they can claim that state support will keep their state from "falling
behind." While state financial problems may handicap state efforts to initiate or
expand stem cell programs, the evidence to date suggests these programs will
continue, albeit on a less well-funded basis. There will be increasingly vocal
debates over royalties, product pricing, and other research management issues
that will be resolved in a wide range of ways, and conflicts between the rules that
apply to collaborating researchers located in different states. This system is less
efficient and more administratively difficult than a single funding source and set
65. For an example of this rhetoric, see Deval L. Patrick & Therese Murray, The Promise of
Biotech, BOSTON GLOBE, May 9, 2007, at A9.
66. See Levine, supra note 19.
67. LAURENCE BAKER & BRUCE DEAL, CIRM - INTERIM ECONOMIC IMPACT REVIEW (2008),
http://www.cirm.ca.gov/pub/pdf/EcoEval_091008_rpt.pdf.
68. Aaron D. Levine, Research Policy and the Mobility of US Stem Cell Scientists, 24 NATURE
BIOTECHNOLOGY 865 (2006).
69. For an example of the coverage of the Singapore program, see Terri Somers, Singapore
Makes Investment in its Survival, SAN DIEGO UNION-TRIB., Dec. 18, 2006, at Al.
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of rules would be, but it is an accurate reflection of the conflicting and diverse
national public and political views about hESCs, which do not show any sign of
going away anytime soon.
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APPENDIX A. ESTIMATES OF NIH FUNDING FOR STEM CELL RESEARCH,
FEDERAL FISCAL YEARS 2004 TO 2008, IN MILLIONS
70
FY 2004 FY 2005 FY 2006 FY 2007 FY 2008
Actual Actual Actual Actual* Estimate
Stem Cell
Rese l $553 $609 $643 $968 $938Research Total
Human Embryonic $24 $40 $38 $74 $88
Non-Human $89 $97 $110 $120 $150
Embryonic
HumanNnmbn $203 $199 $206 $226 $297Non-Embryonic
Non-Human Non- $236 $273 $289 $400 $497
Embryonic
*In FY 2007, NIH restructured its categorization of disease research. These
figures are using the new structure, although NIH also released information for
FY 2007 using the historical method of categorizing diseases.
70. National Institutes of Health, Research Portfolio Online Reporting Tool,
http://report.nih.gov/rcdc/categories/Default.aspx (last visited Apr. 30, 2009) (noting that estimates
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APPENDIX B. STATE GOVERNMENT SUPPORT FOR STEM CELL
RESEARCH, IN MILLIONS
State Allocated to Date Appropriated or Authorized But Not Allocated*
California71  $693 $3,000
Connecticut 72  $30 $100
Illinois 73  $15 --
Maryland 74  $38 $18
Massachusetts 75  $20.2 $980
Minnesota 76  $15 --
New Jersey77  $5 $280
71. California Institute for Regenerative Medicine, supra note 22; Around the Regions: With
State Finances Squeezed, California Stem Cell Funding Agency Eyes Contingency Plan,
BIOREGION NEWS, Jan. 5, 2009, http://www.genomeweb.com/bioregionnews/around-regions (free
subscription required for access).
72. Press Release, Conn. Dep't of Pub. Health, State of Connecticut Prepares to Allocate $9.8
Million in Stem Cell Research Funds (Apr. 1, 2009) http://www.ct.gov/dph/cwp/
view.asp?Q=437842&A=3659 (noting this is the third installment of grants).
73. Governor Blagojevich announced $10 million in grants in April 2006 and $5 million in
August 2006. See Press Release, Ill. Regenerative Med. Inst., Gov. Blagojevich Announces
Recipients of $5 Million in New State Stem Cell Research Funding (Aug. 17, 2006),
http://www.idph.state.il.us/irmi/news_081706.html; Press Release, I11. Regenerative Med. Inst.,
Gov. Blagojevich, Comptroller Hynes Announce $10 million in State Stem Cell Research Grants
(Apr. 24, 2006), http://www.idph.state.il.us/irmi/news_042406.html.
74. The Maryland Stem Cell Research Fund had a budget of $15 million in FY 2007, $23
million in FY 2008 and $18 million in FY 2009. See Press Release, Md. Stem Cell Research Fund,
Maryland Stem Cell Commission Announces that 24 Grant Agreements Have Been Signed (Jan.
22, 2008), available at http://www.mscrf.org/media/client/pdf/mscrcommission/publicnotices/
stemcellannualreport2007press.pdf, Press Release, Md. Stem Cell Research Fund, Maryland Stem
Cell Research Commission Receives 147 Applications for Funding (Jan. 16, 2009), available at
http://www.mscrf.org/-media/client/pdf/MSCRFApplications-AnnualReport-Final.pdf.
75. The Massachusetts Life Sciences Initiative ($1 billion) is not solely for stem cell research.
See The Massachusetts Life Sciences Center, supra note 29. The Center awarded $8.2M to the
University of Massachusetts for a stem cell bank and $12M in matching funds. Press Release, Univ.
of Mass. Med. Sch., Massachusetts Life Sciences Center Awards $8.2 Million to UMass Medical
School for Stem Cell Bank and International Registry, $12M for Matching Grants (Oct. 29, 2007),
http://www.umassmed.edu/10 26_07.aspx.
76. This was a capital grant by University of Minnesota to Minnesota Stem Cell Institute.
University of Minnesota, Stem Cell Institute, About Us, http://www.stemcell.umn.edu/stemcelU
about/home.html (last visited Apr. 30, 2009).
77. New Jersey authorized $5 million in one round of research grants in 2005. The
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*Dashes in this column indicate that the quantity of non-allocated funds is
unknown or zero.
appropriated/authorized amount includes $10 million for research grants and $270 million for stem
cell lab construction. State of New Jersey Commission on Science & Technology, Stem Cell
Research in New Jersey, http://www.state.nj.us/scitech/stemcell (last visited Apr. 30, 2009).
78. New York State Stem Cell Science, Grants and Contracts Awarded,
http://stemcell.ny.gov/researchsupport-grantsawards.html (last visited Apr. 30, 2009). In
November of 2008, the Health Department deferred payment of $9 million in stem cell spending.
See Alex Philippidis, NY Gov.'s FY '10 Budget Would Cleave $5.2B from Life-Science-Related
Programs, BIOREGION NEWS, Nov. 17, 2008, http://www.genomeweb.com/ bioregionnews/ny-
gov%E2%80%99s-fy%E2%80%9910-budget-cuts-would-cleave-52b-life-science-related-programs
(free subscription required for access).
79. Separate allocations for non-embryonic stem cell research were made in 2003 and 2006 to
the Center for Stem Cell & Regenerative Medicine. National Center for Regenerative Medicine,
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State Recipient Donors Donated Comments
(Millions)
California
Institute for Variety of





Bond anticipation for research
81 ~~notes "purchased frrsac




Maryland82  Johns Hopkins Michael $100 hESC research
University Bloomberg is unclear
80. See, e.g., LAURENCE BAKER & BRUCE DEAL, ANALYSIS GROUP, CIRM - INTERIM ECONOMIC
IMPACT REvIEW, ADDENDUM 1: ECONOMIC EFFECT OF CIRM FACILITIES AND EQUIPMENT GRANTS
ON TAX REVENUES AND JOBS (SEPTEMBER 10, 2008), available at http://www.cirm.ca.gov/
pub/pdf/EcoEval_091008_Addendum.pdf, Richard C. Paddock, Broads Donate $25 Million for
Stem Cell Research Lab, L.A. TIMES, Dec. 18, 2008, at B3; Terri Somers, Donations Add Muscle to
Bid for Stem Cell Institute Funds, SAN DIEGO UNION-TRIB., Feb. 29, 2008, at C-i; Richard C.
Paddock, Broads Donate $25 Million for Stem Cell Research Lab, L.A. TIMES, Dec. 18, 2008, at
B3; Terri Somers, Stem-Cell Researchers Celebrate $30 Million Donation, SAN DIEGO UNION-
TRIB., Sept. 16, 2008, http://www.signonsandiego.com/news/metro/20080916-1858-
bnl6stems.html; Oliver Staley, Stanford Gets $75 Million for Stem Cells Research from Lokey,
BLOOMBERG.COM, Oct. 6, 2008, http://www.bloomberg.com/apps/news?pid=206011
03&sid=aH.JjGHbrwA4&refer=us; UCSF Snags $25 Million Stem Cell Donation, California Stem
Cell Report, Dec. 18, 2008, http://californiastemcellreport.blogspot.com/2008/12/ucsf-snags-25-
million-stem-cell.html.
81. BAKER & DEAL, supra note 67, at 9.
82. Sonya Geis, Rich Donors Help Calif Fund Stem Cell Research, WASH. POST, Dec. 19,
2006, at A2, available at http://www.washingtonpost.com/wp-dyn/content/article/
2006/12/18/AR2006121801080.html (noting that this donation was "largely for stem cell
research"); Winnie Hu, New York: Bloomberg Donates $100 Million to University, N.Y. TIMES,
Feb. 3, 2006, at B4.
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83. Press Release, Johns Hopkins Univ. Sch. of Med., Hopkins Launches Cell Engineering
Institute with $58.5 M. Gift (Jan. 30, 2001), available at http://www.hopkinsmedicine.org/
press/200 1/JANUARY/010130.HTM.
84. HARVARD STEM CELL INST., CONNECTIVITY: HARVARD STEM CELL INSTITUTE ANNUAL
REPORT 32 (2006), available at http://www.hsci.harvard.edu/files/HSCIAnnualReport_2006.pdf.
85. Campaigning for Stem Cells, NEW ATLANTIS, Spring 2004, at 93, 94; Harvard Stem Cell
Studies Raise Eyebrows, FOXNEwS.coM, Apr. 12, 2005, http://www.foxnews.com/story/
0,2933,153130,00.html.
86. Commonwealth of Massachusetts, supra note 47, at 2 (projecting "$250 million in private
sector matching funds for capital, research grants, fellowships, and workforce training").
87. See Constance Holden, States, Foundations Lead the Way After Bush Vetoes Stem Cell Bill,
313 SCIENCE 420 (2006).
88. Stowers Institute for Medical Research, Fact Sheet, http://www.stowers-institute.org/
MediaCenter/docs/FactSheet.pdf (last visited Apr. 30, 2009).
Amount
State Recipient Donors Donated Comments
(Millions)
Johns Hopkins




4 Harvard Stem Juvenile Diabetes $100 millionMassachusetts84  Cell ste Research $40 target 85Cell Institute Foundation;
Harvard; other
philanthropists
Funds provided Unclear if
in conjunction donations










Missouri88  Medical James and Virginia $2,000 donation of
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Amount

















New York9' Sloan-Kettering Geoffrey Beene, $101.9 shares; funds







92 Medicine-New York Black Family Leon D. Black $10
Stem Cell
Institute
89. Press Release, Mem'l Sloan-Kettering Cancer Ctr., Stem Cell Research in New York City
Receives Pivotal Boost from The Starr Foundation (May 23, 2005),
http://www.mskcc.org/mskcc/html57616.cfm.
90. Press Release, Rockefeller Univ., Rockefeller University Establishes Stem Cell Research
Center (Aug. 3, 2004), http://runews.rockefeller.edu/index.php?page=engine&id=42.
91. Press Release, Mem'l Sloan-Kettering Cancer Ctr., New Geoffrey Beene Gift to Memorial
Sloan-Kettering Puts Total Support Over $100 Million (Oct. 9, 2008),
http://www.mskcc.org/mskcc/html/87852.cfm.
92. Mount Sinai School of Medicine Establishes Stem Cell Institute, MED. NEWS TODAY, May
6, 2005, http://www.medicalnewstoday.com/articIes/23926.php.
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93. Press Release, Columbia Univ. Med. Ctr., Columbia University Medical Center Launches
Multi-Year Campaign To Support Stem Cell Research (June 15, 2005),
http://www.cumc.columbia.edu/news/press-releases/stem-cell-initiative.html.
94. Robert Kolker, The California Stem-Cell Gold Rush, N.Y. MAG., Dec. 27, 2004, available
at http://nymag.com/nymetro/health/features/10755/index3.html.
95. Press Release, New York Stem Cell Found., The New York Stem Cell Foundation
Commits More than $5 Million in Fellowships for New York Scientists Engaged in Human
Embryonic Stem Cell Research (June 28, 2007), available at
http://www.nyscf org/images/pdf/pr-fellowship-07-28-07.pdf; see also The New York Stem Cell
Foundation, Fellowships & Grants, http://www.nyscf.org/fellowshipsgrants/fellowships
._grants.html (last visited Apr. 30, 2009).
96. Press Release, Univ. of Rochester Med. Ctr., Medical Center Receives Gift for Stem Cell
Research (Aug. 10, 2006), http://www.urmc.rochester.edu/PR/news/story.cfm?id=1 201.
Amount
State Recipient Donors Donated Comments
(Millions)
Columbia Total $50
New York93  University Various pivate $25 million goal
Medical Center philanthropists
Weill-Cornell's
New York94  Ansary Center Shahla and $15





New York 95  Post-doctoral Stanley and Fiona 
also
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97. Albert Einstein College of Medicine, Einstein Receives $25-Million Gift to Support Stem
Cell and Epigenomic Research and Clinical Skills Training, http://www.aecom.yu.edu/home/
fullstory.asp?id=198 (last visited Apr. 30, 2009) (noting that "$15 million will be used to establish
the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research");
see also New York City Bioscience Initiative, Funding for Stem Cell Research,
http://www.nycbiotech.org/stem-cell.html (last visited Apr. 30, 2009).
98. Amber Buckley, Anonymous Donor Pledges $25 Million to Stem Cell Research,
DISTINCTIONS (Univ. Tx. Health Sci. Ctr., Houston, Tx.), May 2004, http://public
affairs.uth.tmc.edu/distinctions/archive/2004/May/25.html.
99. See Tom Paulson, Private Funds Keep Stem Cell Research Viable in Seattle, SEATTLE
POST-INTELLIGENCER, Sept. 29, 2007, at Al, available at http://www.seattlepi.com/localU
333633_stemcells29.html.
100. Estimates of the amount sought by the University of Washington campaign vary between
$50 million, id., and $100 million, Eric Engleman, $100M Stem-Cell Push: UW Counters Rivals,
PUGET SoUND Bus. J., Mar. 10-16, 2006, at 1.
101. See Tom Still, Wisconsin's Private Funding of Stem Cell Research Bucks Coastal Models,
Wis. TECH. NETWORK NEWS, Sept. 8, 2008, http://wistechnology.com/articles/5003.
Amount
State Recipient Donors Donated Comments
(Millions)
Albert Einstein
College of Ruth and David




Sciences Center Anonymous patient $25
at Houston
University of




University of Research investor 
in
Wisconsinl01 Wisconsin Foundation $50 embryonic
stem cell(WARF) research in
Wisconsin
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